Application of 4-amino-1-benzylpiperidine in preparation of medicine for preventing and / or treating acute lung injury

The inadequacy of acute lung injury treatment is solved by inhibiting neutrophil chemotaxis and inflammatory factor release through 4-amino-1-benzylpiperidine, providing an effective drug that significantly improves lung tissue damage.

CN118892484AActive Publication Date: 2024-11-05INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202310486170.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-04
Publication Date
2024-11-05
Estimated Expiration
2043-05-04

AI Technical Summary

Technical Problem

There is a lack of effective drugs in the prior art for the prevention and treatment of acute lung injury, and the activity and use of 4-amino-1-benzylpiperidine are not reported.

Method used

4-amino-1-benzylpiperidine is used to prepare drugs for preventing and treating acute lung injury by inhibiting neutrophil chemotactics, reducing the number of inflammatory cells, reducing the release of inflammatory factors, and improving pathological damage to lung tissue.

Benefits of technology

It significantly inhibits neutrophil chemotactics, reduces lung inflammatory response, and improves lung tissue pathological damage, providing a safe and effective drug for treating acute lung injury.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and discloses an application of 4-amino-1-benzyl piperidine in a medicine for preventing and / or treating acute lung injury. According to the application disclosed by the invention, the effect of the 4-amino-1-benzylpiperidine on preventing and / or treating the acute lung injury is subjected to experimental research through in-vivo and in-vitro models, and a result shows that the 4-amino-1-benzylpiperidine can be used for remarkably inhibiting neutrophil chemotaxis; the number of inflammatory cells and release of inflammatory factors in LPS-induced acute lung injury animal bronchoalveolar lavage fluid are reduced, lung tissue pathological injury is improved, and the compound can be used for preparing protective drugs for acute lung injury. The invention provides new application of 4-amino-1-benzylpiperidine in preparation of acute lung injury protective drugs, and provides a safe, effective and economic solution for treatment and prevention of acute lung injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a new application of 4-amino-1-benzylpiperidine in drug preparation, and relates to a pharmaceutical composition containing 4-amino-1-benzylpiperidine; and relates to the application of 4-amino-1-benzylpiperidine and the pharmaceutical composition thereof in preparing drugs for preventing and / or treating acute lung injury, and belongs to the field of medical technology. Background Art

[0002] Respiratory diseases have a high incidence rate and a heavy disease burden. Common respiratory diseases, whether acute (such as acute lung injury, bacterial pneumonia, viral pneumonia, etc.) or chronic (COPD, asthma, bronchiectasis, pulmonary fibrosis, etc.), all involve airway inflammation and varying degrees of airway structure and function damage. Therefore, improving airway inflammation and protecting airway function are the main treatment strategies for respiratory diseases. Glucocorticoids are used to treat respiratory diseases by inhibiting airway inflammation, including acute lung injury / acute respiratory distress syndrome, COPD, asthma, etc. caused by various reasons, but they increase the risk of lung infection and have a variety of side effects such as endocrine disorders, gastrointestinal ulcer bleeding, femoral head necrosis, etc. New safe and effective drugs for the treatment of respiratory diseases are urgently needed clinically.

[0003] Acute lung injury is caused by various non-cardiogenic pathogenic factors inside and outside the lungs, which damages the pulmonary capillary endothelial cells and alveolar epithelial cells, and then causes damage to the alveolar capillary barrier, infiltration of inflammatory cells in the lungs, diffuse alveolar and interstitial edema, leading to acute hypoxic respiratory insufficiency, which is often manifested clinically as dyspnea and hypoxemia. In severe cases, it can develop into acute respiratory distress syndrome, respiratory failure, etc., and even endanger life. The mortality rate after illness is as high as 30% to 50%. Even if they survive, their lung function is severely damaged, affecting the quality of life of patients, and bringing huge medical and economic burdens to patients, families and society.

[0004] Neutrophils play a key role in the occurrence and development of acute lung injury. Once they are recruited from the blood circulation to the lung tissue, they will release cytotoxic molecules, leading to lung tissue damage. The pathological changes of acute lung injury are mainly the aggregation of a large number of neutrophils and the destruction of the alveolar-capillary barrier. The uncontrolled inflammatory response caused by the aggregation, activation, and apoptosis of a large number of neutrophils is the root cause of acute lung injury caused by various etiologies. In lung injury caused by infectious and non-infectious factors, neutrophils accumulate and activate in the pulmonary microcirculation system, releasing a variety of toxic mediators (including proteases, proinflammatory cytokines, and procoagulant molecules) and degranulation, causing increased vascular permeability and disappearance of endothelial barrier function, ultimately leading to a clinical syndrome characterized by respiratory distress and progressive hypoxemia, which can develop into acute respiratory distress syndrome, respiratory failure, etc. in severe cases.

[0005] At present, the treatment measures for acute lung injury and acute respiratory distress syndrome are still mainly supportive, with the aim of improving gas exchange in the lungs and preventing insufficient oxygen supply to other tissues and organs, and preventing the occurrence of complications. Although there are many drugs used to treat acute lung injury, there is no effective drug that can reduce mortality. Therefore, finding effective drugs for the treatment of acute lung injury has become a research hotspot.

[0006] Currently, there are no reports on the activity of 4-amino-1-benzylpiperidine, nor on its preventive and therapeutic effects on acute lung injury. Summary of the invention

[0007] Based on this, the purpose of the present invention is to provide the use of 4-amino-1-benzylpiperidine in the preparation of a drug for preventing and / or treating acute lung injury to solve the problems existing in the prior art. The present invention finds that 4-amino-1-benzylpiperidine has significant clinical application value by inhibiting neutrophil chemotaxis, reducing the number of inflammatory cells, reducing the release of inflammatory factors, and improving lung tissue pathological damage.

[0008] To achieve the above object, the present invention provides the following solutions:

[0009] The present invention provides the use of 4-amino-1-benzylpiperidine as shown in formula I in preparing a drug for preventing and / or treating acute lung injury.

[0010]

[0011] The 4-amino-1-benzylpiperidine is an organic compound with a molecular formula of C12H18N2 and a molecular weight of 190.29.

[0012] Furthermore, the present invention provides the use of 4-amino-1-benzylpiperidine, or a pharmaceutically acceptable salt, solvate, or a solvate of a salt thereof in the preparation of a drug for preventing and / or treating acute lung injury.

[0013] Furthermore, the acute lung injury is a disease whose main pathological feature is lung inflammation caused by excessive accumulation and activation of neutrophils in lung tissue.

[0014] Furthermore, 4-amino-1-benzylpiperidine treats acute lung injury by alleviating pulmonary inflammatory response.

[0015] Furthermore, the alleviation of lung inflammation includes inhibiting neutrophil chemotaxis, reducing the number of inflammatory cells, reducing the release of inflammatory factors, and improving pathological damage to lung tissue.

[0016] The present invention also provides an application of a pharmaceutical composition in the preparation of a drug for preventing and / or treating acute lung injury, characterized in that the pharmaceutical composition is prepared from 4-amino-1-benzylpiperidine or a pharmaceutically acceptable salt thereof as shown in Formula I and a pharmaceutically acceptable carrier or excipient;

[0017]

[0018] The pharmaceutical preparation can be prepared according to methods known in the art. The 4-amino-1-benzylpiperidine of the present invention can be combined with one or more pharmaceutically acceptable solid or liquid excipients and / or adjuvants to prepare any dosage form for human or animal use. The content of the compound of the present invention in its pharmaceutical composition is usually 0.1-99%.

[0019] Furthermore, the pharmaceutical preparation includes an oral preparation or a dosage form for parenteral administration.

[0020] Furthermore, the oral preparations are tablets, capsules, pills, and liquid preparations; the parenteral administration dosage forms are preparations for intramuscular injection, intravenous injection, intravenous drip, skin administration, and mucosal administration.

[0021] The dosage form can be a liquid dosage form, a solid dosage form or a semisolid dosage form. Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including o / w types, w / o types and multiple emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops, nasal drops, lotions and liniments, etc.; solid dosage forms can be tablets (including ordinary tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric-coated capsules), granules, powders, micropills, dropping pills, suppositories, films, patches, aerosols (powders), sprays, etc.; semisolid dosage forms can be ointments, gels, pastes, etc.

[0022] The compound of the present invention can be made into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle drug delivery systems.

[0023] In order to prepare the compound of the present invention into tablets, various excipients known in the art can be widely used, including diluents, binders, wetting agents, disintegrants, lubricants, and glidants. The diluent may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent may be water, ethanol, isopropanol, etc.; the binder may be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, carboxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinyl pyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.

[0024] The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.

[0025] In order to prepare the dosing unit into a capsule, the active ingredient compound of the present invention can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard capsule or a soft capsule. The active ingredient compound of the present invention can also be first prepared into granules or pellets with a diluent, a binder, and a disintegrant, and then placed in a hard capsule or a soft capsule. The diluents, binders, wetting agents, disintegrants, and glidants used to prepare tablets of the compound of the present invention can also be used to prepare capsules of the compound of the present invention.

[0026] To prepare the compound of the present invention into an injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent and an appropriate amount of a solubilizer, a cosolvent, a pH adjuster, and an osmotic pressure regulator commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc.; the pH adjuster can be phosphate, acid salt, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. If a lyophilized powder injection is prepared, mannitol, glucose, etc. can also be added as a support agent.

[0027] In addition, if necessary, colorants, preservatives, spices, flavoring agents or other additives may also be added to the pharmaceutical preparation. In order to achieve the purpose of medication and enhance the therapeutic effect, the medicine or pharmaceutical composition of the present invention can be administered by any known method of administration. The dosage of the pharmaceutical composition of the compound of the present invention can vary widely according to the nature and severity of the disease to be prevented or treated, the individual conditions of the patient or animal, the route of administration and the dosage form, etc. Generally speaking, the daily suitable dosage range of the compound of the present invention is 0.001-100 mg / kg body weight. The above dosage can be administered in one dosage unit or divided into several dosage units, depending on the doctor's clinical experience and the dosage regimen including the use of other treatment means.

[0028] The compound of the present invention can be taken alone or in combination with other therapeutic drugs or symptomatic drugs. When the compound of the present invention has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 4-Amino-1-benzylpiperidine inhibits chemotaxis of neutrophils in vitro.

[0030] Figure 2 4-Amino-1-benzylpiperidine reduces the wet / dry weight ratio of lung tissue in acute lung injury.

[0031] Figure 3 4-Amino-1-benzylpiperidine reduces the number of inflammatory cells in bronchoalveolar lavage fluid in acute lung injury.

[0032] Figure 4 4-Amino-1-benzylpiperidine reduces the release of inflammatory factors in bronchoalveolar lavage fluid in acute lung injury.

[0033] Figure 5 4-Amino-1-benzylpiperidine improves pathological changes in lung tissue after acute lung injury. DETAILED DESCRIPTION

[0034] In order to make the objectives, technical solutions and advantages of the present invention more clear, the present invention will be further described in detail below with reference to the accompanying drawings.

[0035] Example 1: Effect of 4-amino-1-benzylpiperidine on chemotaxis of neutrophils in vitro

[0036] Male SD rats weighing 140-160g were selected for the experiment. They were anesthetized with chloral hydrate and blood was collected from the abdominal aorta. Peripheral blood was first extracted from the rats and then separated. 3.8% sodium citrate solution was added at a ratio of 1:9 for anticoagulation to separate neutrophils. The isolated neutrophils were identified by trypan blue exclusion test and Giemsa staining test, and their cell viability and purity were greater than 90%. The extracted cells were cultured in 96-well chemotaxis plates using RPMI-1640 medium. The cells were divided into normal control group, model group, model + positive drug group (10μg / mL), and model + 4-amino-1-benzylpiperidine group (1, 3, 10μg / mL); 50μL of neutrophils (density: 5×10 4 / mL), RPMI-1640 medium was added to the lower chamber of the normal group, RPMI-1640 medium (1μM) containing chemotactic peptide was added to the lower chamber of the model group, and RPMI-1640 medium containing chemotactic peptide and drug was added to the lower chamber of the drug-treated group. The cells were cultured in an incubator at 37 degrees and 5% CO2 for 3 hours, then the liquid in the upper chamber was aspirated, Giemsa stain was added to the lower chamber for staining, and then pictures were collected and the number of cells was counted using an inverted microscope.

[0037] The results are as follows Figure 1 As shown, compared with the normal control group, the chemotaxis of neutrophils in the model group was significantly increased. Compared with the model group, 4-amino-1-benzylpiperidine can inhibit neutrophil chemotaxis in a dose-dependent manner, among which the high-dose group has the most obvious effect. The experimental results show that 4-amino-1-benzylpiperidine can inhibit the chemotaxis of neutrophils.

[0038] Table 1 Effect of 4-amino-1-benzylpiperidine on neutrophil chemotaxis in vitro.

[0039]

[0040] Example 2: Effect of 4-amino-1-benzylpiperidine on wet / dry weight ratio of lung tissue in acute lung injury

[0041] BALB / c mice were purchased from Weitonglihua (Beijing Weitonglihua Experimental Animal Technology Co., Ltd.), with a weight range of 18-22g, and were anesthetized by isoflurane. 20-30 minutes after anesthesia, 50μl (concentration of 8mg / ml) of LPS, a total of 400μg, was instilled into the nose; the normal control group mice were instilled with the same volume of saline. After modeling, the mice were placed in a 37℃ constant temperature system. The mice in each group were fasted the night before modeling. Half an hour and 12 hours after the mice inhaled LPS, the mice were intraperitoneally injected with 4-amino-1-benzylpiperidine prepared with saline according to the dose, and the normal control group and the model group were given the corresponding volume of saline. The experiment was divided into sham operation group, model group, positive drug group (sodium sivelestat, 50mg / kg), and 4-amino-1-benzylpiperidine (25, 50, 100mg / kg). Samples were collected 24 hours after modeling, the wet weight of the left lung was measured, and then baked in a constant temperature oven at 60 degrees for 48 hours until the dry weight was constant. The dry weight was then measured to calculate the wet-to-dry weight ratio (W / D) of the lung.

[0042] The results are as follows Figure 2 As shown in the figure, compared with the normal control group, the lung W / D of the model group increased significantly. Compared with the model group, 4-amino-1-benzylpiperidine can reduce pulmonary edema caused by acute lung injury in a dose-dependent manner, among which the high-dose group had the most obvious effect. The experimental results show that 4-amino-1-benzylpiperidine can significantly improve pulmonary edema caused by acute lung injury.

[0043] Table 2 Effect of 4-amino-1-benzylpiperidine on the wet / dry weight ratio of lung tissue in acute lung injury.

[0044]

[0045] Example 3: Effect of 4-amino-1-benzylpiperidine on the number of inflammatory cells in bronchoalveolar lavage fluid of acute lung injury.

[0046] The animal modeling and administration methods were the same as those in Example 3. 24 hours after acute lung injury, bronchoalveolar lavage was performed, and the perfusate was collected for cell classification and counting, and then the number of inflammatory cells was counted using Giemsa staining.

[0047] The results are as follows Figure 3 As shown in the figure, 24 hours after acute lung injury, the number of total cells, neutrophils, and macrophages in the bronchoalveolar lavage fluid of the model group mice was significantly increased compared with the normal control group. Compared with the model group, all doses of 4-amino-1-benzylpiperidine can reduce the number of total cells, neutrophils, and macrophages, and the high-dose group has the most obvious effect. The experimental results show that 4-amino-1-benzylpiperidine can significantly reduce the increase in the number of inflammatory cells caused by acute lung injury.

[0048] Table 3 Effect of 4-amino-1-benzylpiperidine on the number of inflammatory cells in bronchoalveolar lavage fluid in acute lung injury.

[0049]

[0050] Example 4: Effect of 4-amino-1-benzylpiperidine on the concentration of inflammatory factors in bronchoalveolar lavage fluid of acute lung injury.

[0051] The animal modeling and administration methods were the same as those in Example 3. 24 hours after acute lung injury, bronchoalveolar lavage was performed, and the expression levels of IL-6, TNF-α and IL-1β in the bronchoalveolar lavage fluid were detected by a kit.

[0052] The results are as follows Figure 4 As shown in the figure, 24 hours after acute lung injury, the concentrations of IL-6, TNF-α and IL-1β in the bronchoalveolar lavage fluid of the model group mice were significantly increased compared with the normal control group. Compared with the model group, 4-amino-1-benzylpiperidine dose-dependently reduced the concentration of inflammatory factors, and the high-dose group had the most obvious effect. The experimental results show that 4-amino-1-benzylpiperidine can significantly improve the release of inflammatory factors caused by acute lung injury.

[0053] Table 4 Effect of 4-amino-1-benzylpiperidine on the release of inflammatory factors in bronchoalveolar lavage fluid of acute lung injury.

[0054]

[0055] Example 5: Effect of 4-amino-1-benzylpiperidine on pathological changes of lung tissue after acute lung injury.

[0056] The animal modeling and administration methods were the same as those in Example 3. After 24 hours of acute lung injury, the left lung was removed, and part of the left lung tissue was fixed in 4% paraformaldehyde solution for 48 hours for pathological section analysis.

[0057] The results are as follows Figure 5 As shown in the figure, 24 hours after acute lung injury, the alveolar capillaries of the model group mice were diffusely dilated, the pulmonary interstitium and alveolar septa were significantly widened, and a large number of inflammatory cells infiltrated compared with the normal control group. Compared with the model group, the above changes in the high-dose 4-amino-1-benzylpiperidine group were significantly alleviated, and the changes in lung tissue structure after acute lung injury can be significantly improved. The experimental results show that 4-amino-1-benzylpiperidine can significantly improve the pathological changes in lung tissue caused by acute lung injury.

[0058] In summary, the present invention investigates the therapeutic effect of 4-amino-1-benzylpiperidine on acute lung injury through in vitro neutrophil and acute lung injury animal models. The results show that in vitro experiments, 4-amino-1-benzylpiperidine significantly inhibits the chemotaxis of neutrophils. In vivo experiments, intraperitoneal injection of 4-amino-1-benzylpiperidine can significantly reduce the number of inflammatory cells and the release of inflammatory factors in bronchoalveolar lavage fluid caused by LPS, and improve lung tissue pathological damage. Therefore, 4-amino-1-benzylpiperidine has the effect of preventing and / or treating acute lung injury. 4-amino-1-benzylpiperidine is used as an active substance, used alone or / with other pharmacologically active compounds and / or extracts to form a compound, and various dosage forms of anti-acute lung injury drugs are prepared according to conventional preparation methods in the field of pharmacy, or compound preparations are prepared with other anti-acute lung injury drugs, etc., which are used to reduce adverse reactions in drug action while maintaining the therapeutic effect, and can provide a safe, effective and economical solution for the prevention and treatment of acute lung injury.

[0059] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described with reference to the preferred embodiments of the present invention, it should be understood by those skilled in the art that various changes may be made in implementation and details without departing from the spirit and scope of the present invention as defined in the appended claims.

Claims

1. Use of 4-amino-1-benzylpiperidine or a pharmaceutically acceptable salt thereof as shown in formula I in the preparation of a drug for preventing and / or treating acute lung injury; 2. The use according to claim 1, characterized in that: The acute lung injury is an acute, persistent pulmonary inflammatory response syndrome that causes diffuse pulmonary interstitial and edema by damaging alveolar epithelial cells and capillary endothelial cells, leading to progressive hypoxemia, non-cardiogenic pulmonary edema and acute respiratory distress syndrome.

3. The use according to claim 2, characterized in that: The acute lung injury is a disease whose main pathological feature is lung inflammation caused by excessive accumulation and activation of neutrophils in lung tissue.

4. The use according to claim 1, characterized in that: 4-Amino-1-benzylpiperidine treats acute lung injury by alleviating pulmonary inflammatory response.

5. The use according to claim 4, characterized in that: The reduction of lung inflammation includes inhibiting neutrophil chemotaxis, reducing the number of inflammatory cells, lowering the release of inflammatory factors, and improving pathological damage to lung tissue.

6. The use according to claim 5, characterized in that: The inflammatory cells include neutrophils, eosinophils, monocytes, macrophages, and lymphocytes; the inflammatory factors include TNF-α, IL-6, IL-1β, and chemokines.

7. Use of a pharmaceutical composition in the preparation of a drug for preventing and / or treating acute lung injury, characterized in that: The pharmaceutical composition is prepared from 4-amino-1-benzylpiperidine or a pharmaceutically acceptable salt thereof as shown in formula I and a pharmaceutically acceptable carrier or excipient; 8. Use according to claim 7, characterized in that The pharmaceutical composition can be prepared into an oral preparation or a dosage form for parenteral administration.

9. The use according to claim 8, characterized in that The oral preparations include tablets, capsules, pills, and liquid preparations; the non-digestive tract administration dosage forms include preparations for intramuscular injection, intravenous injection, intravenous drip, skin administration, and mucosal administration.

10. The use according to claim 8, characterized in that The oral preparation can be prepared as a sustained-release or controlled-release preparation.

Citation Information

Patent Citations

  • Use of 4-aminopiperidine compound

    CN108553464A

  • Application of fluorofenidone in preparation of medicine for treating acute lung injury

    CN113274389A

  • Application of 3-aryl benzofuran derivative EAPP-2 in preparation of medicine for treating chronic obstructive pulmonary disease

    CN114099491A

  • Application of micromolecular diterpenoid compound or salt thereof in preparation of medicine for preventing and treating acute lung injury

    CN114191423A

  • Novel benzylpiperidine compound

    CN1505626A